Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption
Wang Y, Zhou Y, Zheng Z, Li J, Yan Y, Wu W
Cell death & disease · 38 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Células o muestras de laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Natural Science Foundation of China
- Subvenciones
- National Natural Science Foundation of China (81601993); National Natural Science Foundation of China (81272843); National Natural Science Foundation of China (81272843 and 81601993); National Natural Science Foundation of China (81901993)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-11-14 · Cell Death Dis · vol. 9 · número 11 · pág. 1134
- Editorial
- Springer Nature
- Citado
- 56 citas · más que el 89% de estudios similares · 2.2× el promedio de su campo
- Referencias
- 51 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Histone Deacetylase Inhibitors Research · Synthesis and biological activity
- Palabras clave
- Sulforaphane, Paclitaxel, XIAP, Downregulation and upregulation, Apoptosis, Tubulin, Chemistry, Cancer research, Microtubule, Biology, Caspase, Programmed cell death, Cell biology, Cancer, Biochemistry
- MeSH
- microtubules, humans, carcinoma, non-small-cell lung, lung neoplasms, paclitaxel, isothiocyanates, sulfoxides, proteasome endopeptidase complex, tubulin, mitogen-activated protein kinase 1, mitogen-activated protein kinase 3, rna, small interfering, antineoplastic agents, drug combinations, signal transduction, apoptosis, cell proliferation, gene expression regulation, neoplastic, drug resistance, neoplasm, aged, middle aged, female, male, hsp70 heat-shock proteins, neoplasm grading, a549 cells
6 autores
- Yalin Wang🇨🇳Capital Medical University
- Yan Zhou🇨🇳Capital Medical University
- Zhongnan Zheng🇨🇳Capital Medical University
- Juntao Li🇨🇳Capital Medical University
- Yu‐Ting Yan🇨🇳Capital Medical University
- Wei Wu🇨🇳 · autor de correspondenciaCapital Medical University; Chinese Institute for Brain Research; Beijing Institute for Brain Disorders
Resumen
El texto original del estudio, en el idioma en que se publicó.
Long treatment with paclitaxel (PTX) might increase resistance and side-effects causing a failure in cancer chemotherapy. Here we uncovered that either sulforaphane-cysteine (SFN-Cys) or sulforaphane-N-acetyl-cysteine (SFN-NAC) induced apoptosis via phosphorylated ERK1/2-mediated upregulation of 26 S proteasome and Hsp70, and downregulation of βIII-tubulin, XIAP, Tau, Stathmin1 and α-tubulin causing microtubule disruption in human PTX-resistant non-small cell lung cancer (NSCLC) cells. Knockdown of either βIII-tubulin or α-tubulin via siRNA increased cell sensitivity to PTX, indicating that these two proteins help cells increase the resistance. Tissue microarray analysis showed that overexpression of βIII-tubulin correlated to NSCLC malignant grading. Immunofluorescence staining also showed that SFN metabolites induced a nest-like microtubule protein distribution with aggregation and disruption. Co-immunoprecipitation showed that SFN metabolites reduced the interaction between βIII-tubulin and Tau, and that between α-tubulin and XIAP. The combination of PTX with SFN metabolites decreased the resistance to PTX, and doses of both PTX and SFN metabolites, and enhanced apoptosis resulting from activated Caspase-3-caused microtubule degradation. Importantly, the effective dose of SFN metabolites combined with 20 nM PTX will be low to 4 μM. Thus, we might combine SFN metabolites with PTX for preclinical trial. Normally, more than 20 μM SFN metabolites only leading to apoptosis for SFN metabolites hindered their applications. These findings will help us develop a low-resistance and high-efficiency chemotherapy via PTX/SFN metabolites combination.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.